Lamotrigine Generic "A" — Competitive Intelligence Brief

Lamotrigine Generic "A" (Lamotrigine Generic "A") competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant / Mood stabilizer. Area: Neurology / Psychiatry.

marketed Anticonvulsant / Mood stabilizer Voltage-gated sodium channels; glutamate release inhibition Neurology / Psychiatry Small molecule

Target snapshot

Lamotrigine Generic "A" (Lamotrigine Generic "A") — University of Cincinnati. Lamotrigine blocks voltage-gated sodium channels and inhibits glutamate release, reducing neuronal excitability.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lamotrigine Generic "A" TARGET	Lamotrigine Generic "A"	University of Cincinnati	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Lamotrigine (drug)	Lamotrigine (drug)	MaineHealth	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels; glutamate release inhibition
Standard dose lamotrigine	Standard dose lamotrigine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant / Antiepileptic drug	Voltage-gated sodium channels; glutamate release inhibition
lamotrigine (brand Lamictal)	lamotrigine (brand Lamictal)	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Lamictal TM	Lamictal TM	Central Mental Clinic for Outpatients of Baku City	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
Generic lamotrigine	Generic lamotrigine	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition
lamotrigine (generic Teva)	lamotrigine (generic Teva)	University of Maryland, Baltimore	marketed	Anticonvulsant / Mood stabilizer	Voltage-gated sodium channels; glutamate release inhibition

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant / Mood stabilizer class)

1. University of Maryland, Baltimore · 4 drugs in this class
2. Sanofi · 2 drugs in this class
3. University of Cincinnati · 2 drugs in this class
4. Mario Negri Institute for Pharmacological Research · 1 drug in this class
5. Central Mental Clinic for Outpatients of Baku City · 1 drug in this class
6. The University of Texas Health Science Center at San Antonio · 1 drug in this class
7. University Hospitals Cleveland Medical Center · 1 drug in this class
8. Dhaka Medical College · 1 drug in this class
9. Korea Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class